mutations, in whom rituximab appears to obtain minimal extra worth.59 Other genomic subgroups, such as individuals with BIRC3Procedure for relapsed/refractory disease must be made a decision based on prior therapy and likewise The rationale why the original treatment method was no more acceptable (e.g., refractoriness vs. intolerance). Ibrutinib is